() () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () ()

Tag Archives: Strategic Investment

Auxly Cannabis Group and Kaneh Bosm BioTechnology Inc. Announce Strategic Investment and Partnership and Name Change of KBB to ICC International Cannabis Corp.

Sept. 17, 2018 (GLOBE NEWSWIRE) -- Auxly Cannabis Group Inc. (TSX.V: XLY) (OTCQX: CBWTF) ("Auxly" or the "Company") and Kaneh Bosm BioTechnology Inc. (CSE: KBB)(FWB: 8K51)(OTC: KNHBF) ("Kaneh Bosm") are pleased to announce that Auxly has completed a strategic investment (the “Investment”) and has entered into a commercial rights agreement (the “Agreement” and together with the Investment, the “Transaction”) with Kaneh Bosm. The Transaction provides Auxly access to a significant and established portfolio of international cannabis licences, assets and distribution networks. As a result of the Transaction, Auxly believes that it has substantially accelerated its entry into numerous international cannabis markets and partnered with an ambitious team focused on future growth. 
Read more

Inner Spirit Holdings Makes Strategic Investment in High Times Holdings Corp.

Sept. 13, 2018 /CNW/ - Inner Spirit Holdings Ltd. ("Inner Spirit" or "the Company") (CSE:ISH), a specialty retailer and franchisor establishing recreational cannabis dispensaries across Canada under the Spiritleaf brand, today announced that it has made a strategic investment in High Times Holdings Corp. ("High Times"), acquiring 10,000 shares of High Times for $110,000USD. The investment is part of High Times' crowdfunding campaign in anticipation of its planned NASDAQ listing later this year. In connection with the investment, Inner Spirit has been granted the right to, among other things, distribute High Times magazine in Spiritleaf stores across Canada. 
Read more

Pharmagreen Biotech, Inc. Strategic Relationship with Alliance Growers Inc.

Pharmagreen Biotech, (OTC PINKS: AITGD),  a cannabis biotech company focused on producing cannabis starter plantlets through its proprietary tissue culture process is pleased to announce that its wholly owned Canadian subsidiary, WFS Pharmagreen Inc., is currently completing its pre-construction phase of its 62,000 square foot  cannabis biotech complex. WFS Pharmagreen has filed for regulatory approval from Health Canada for the cannabis biotech complex. The facility will supply over ten million cannabis tissue culture starter plantlets on an annual basis, operating at full capacity.  The company’s plan is reach over ninety percent of production capacity in the first year. Ten million starter plantlets produced at an average sale price of $8 US per plantlet would generate eighty million US dollars in annual gross revenues.
Read more